ELEKTA TO ENHANCE CANCER TREATMENT ACCURACY WITH ADDITION OF ULTRASOUND TARGETING FROM NORTH AMERICAN SCIENTIFIC

ELEKTA TO ENHANCE CANCER TREATMENT ACCURACY WITH ADDITION OF ULTRASOUND TARGETING FROM NORTH AMERICAN SCIENTIFIC

PRESS RELEASE

Stockholm, August 18, 2004

ELEKTA TO ENHANCE CANCER TREATMENT ACCURACY WITH ADDITION OF ULTRASOUND TARGETING FROM NORTH AMERICAN SCIENTIFIC

Elekta will begin including state-of-the-art ultrasound targeting technology with its linear accelerator platforms, based upon a new worldwide distribution agreement between Elekta and North American Scientific, Inc.

The inclusion of the BAT® SXi image-guided ultrasound technology with Elekta's highly precise digital linear accelerators for radiation therapy will provide clinicians with the ability to more aggressively treat cancer while avoiding damage to surrounding healthy tissue.

BAT is an image-guided targeting system that provides fast ultrasound localization of a treatment target on a daily basis. Currently, it is most commonly used for treating prostate cancer. Combining ultrasound with a 3D tracking system and a touchscreen-based treatment room interface, BAT non-invasively pinpoints tumor targets rapidly and accurately at the time of a radiation therapy treatment.